Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis of PDAC is the lack of early detection, a complex network of signaling pathways and molecular mechanisms, a den...
Saved in:
Main Authors: | Heng‐Chung Kung, Jun Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | MedComm |
Subjects: | |
Online Access: | https://doi.org/10.1002/mco2.216 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
by: Ozden Oz, et al.
Published: (2023-07-01) -
CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis
by: Hong-Fei Yao, et al.
Published: (2025-01-01) -
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma
by: Metoboroghene O. Mowoe, et al.
Published: (2025-01-01) -
Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma
by: Noha Said Helal, et al.
Published: (2025-01-01) -
Association between preoperative exercise tolerance and unplanned readmission in patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma: a retrospective analysis
by: Makoto Onji, et al.
Published: (2025-01-01)